One of the big issues with chemotherapy is that most treatment approaches focus on the tumour itself without paying significant attention to the microenvironment surrounding the tumour. A new method seeks to solve that.
The Novartis CAR-T cell therapy, Kymriah (tisagenlecleucel), will be made available to patients under the age of 25 via the Cancer Drugs Fund.
Neural networks and supervised machine learning (ML) techniques can characterise cells studied using single cell RNA-sequencing (scRNA-seq), scientists from Carnegie Mellon University (CMU) have learnt. This could aid others in identifying new cell subtypes and in discerning diseased cells.
Microfluidics for use in single cell applications is growing in popularity, as scientists are taking advantage of increasing numbers of commercially available systems enabling high throughput analysis of single cells.
A new technology known as “Pattern to Knowledge” (P2K) has been created by researchers at the University of Waterloo to predict the binding of biosequences in only seconds. The new development could radically speed up discovery of new drugs and reduce the need for expensive laboratory tests.
Scientists from Cancer Research UK in Cambridge have advanced research into liquid biopsies for brain tumours by detecting tumour DNA in the fluid around the spine and brain.
If you’ve been part of the GeoMx DSP Technology Access Program, then you’ll already know why this is so exciting. If you haven’t heard about it yet, then you should make sure you’re sitting down – yes it really is that exciting.
Dr. Jonathan Rothberg is a man who needs little introduction, and is now receiving the Association of Molecular Pathology’s (AMP) Award for Excellence in Molecular Diagnostics Services. We spoke to him about his many achievements, his proudest moments, and the future of his fascinating field.
AMP 2018: Decoding the Cancer Genome: Breakthrough AI Technology Quickly Identifies Actionable Mutations
Explosive advances in next-generation sequencing (NGS) have greatly improved the ability to identify actionable cancer mutations, both for solid and hematological malignancies, and sparked a new era of oncology care. But accurate analysis and proper interpretation of the complex genomic data produced by NGS remain key hurdles.
Genomics England names Congenica as its Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service.